Skip to content

EBITDA at other companies

Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-$52.98M-147%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
-$23.99M+10.7%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
-$37.81M+1.8%
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
-$43.19M-104%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
-$19.64M-187%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS

Other financials

Income statement

See full
Revenue$1.3M+50.8%
Operating income-$13.1M+0.2%
Net income-$18.3M-47.4%
EPS (diluted)-$0.32+48.4%

Balance sheet

See full
Cash & equivalents$100.8M+97.9%
Total debt$2.1M-73.2%
Total equity$30.9M-40.1%
Total assets$105.5M+68.0%

Cash flow

See full
Operating cash flow-$11.0M+23.1%
CapEx--100%
Free cash flow-$11.0M+24.6%

Valuation

See full
Market cap$226.92M+666%
Enterprise value$128.2M-3,860%
P/S57.7×+47.8×

Profitability

See full
Operating margin-1,335.2%-512pp
Net margin-2,193.7%-581pp
FCF margin-1,254%

Returns & leverage

See full
Return on equity-209.3%
Debt / equity0.1×-0.1×
Current ratio6.1×-1.9×

Where this comes from

Calculated from CalAmp’s reported figures.

$13.1Mebit+
$520.0KDepreciation Depletion & Amortization
=-$12.55M

The official record: CalAmp’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about CalAmp's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CalAmp's EBITDA?
CalAmp (CAMP) reported EBITDA of -$12.55M in Q1 2026.
How has CalAmp's EBITDA changed year-over-year?
CalAmp's EBITDA increased by 1.0% year-over-year, from -$12.68M to -$12.55M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.